ARTICLE | Clinical News

VX-175 (GW433908): Began Phase III studies

December 4, 2000 8:00 AM UTC

A separate 48-week international trial of >600 treatment-naive patients will compare 3 VX-175 tablets given once per day in combination with Abbott Laboratories' Norvir ritonavir protease inhibitor with Viracept treatment, both in combination with Ziagen and Epivir. ...